ZYXI - Zynex Is Worth 30-50% More Than Its Current Price
Zynex (ZYXI) manufactures and markets FDA-approved electrotherapy devices and related supplies for the treatment of chronic and acute pain and for muscle rehabilitation. There are several catalysts in play that have and are likely to continue to propel the stock share price higher.
Addressable Market
The global pain management market is expected to grow at a CAGR of 8.4% over the next five years, according to Forrester Research. Taglich Brothers research provides a wide range of industry forecasts that positively favor ZYXI.
What was particularly interesting and informative about their report was that